Concepedia

Gerald K. Bayer

GK

4

Publications

174

Citations

4

H-Index

1987

Active since

Affiliations

University of Wisconsin–Green Bay(Current)

Gerald K. Bayer is an author at University of Wisconsin–Green Bay specializing in medicine, cancer therapeutics, and cancer research.

Top concepts

MedicineOncologyCancer TherapyCancer ResearchPharmacotherapyRadiation OncologyHealthNeurologyPathologyImmunology

Publications per year

1987–2013

4

Publications

4

A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

Anne M. Traynor, Ju-Whei Lee, Gerald K. Bayer et al. · Investigational New Drugs · 2009 · 110 citations · Full text

Second Line Treatment, Oncology, Phase Ii Trial +8

Resolution of Acquired Factor X Deficiency and Amyloidosis with Melphalan and Prednisone Therapy

John Camoriano, Gerald K. Bayer, E. J. Walter Bowie · New England Journal of Medicine · 1987 · 42 citations

Translational Medicine, Factor X Deficiency, Autoimmune Disease +13

Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.

Stephen R. Rapp, Doug Case, Ann M. Peiffer et al. · Journal of Clinical Oncology · 2013 · 12 citations

Neuropsychology, Cancer Management, Placebo-controlled Trial +22

Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Brad S. Kahl, James McGovern, Jules H. Blank et al. · Blood · 2004 · 10 citations

Rows per page

1–4 of 4